
|Articles|April 8, 2005
Newly formed company to develop urology drugs
Yamanouchi Pharmaceutical Co., Ltd., and Fujisawa Pharmaceutical Co., Ltd., merged to form a new corporation named Astellas Pharma, Inc.
Advertisement
Yamanouchi Pharmaceutical Co., Ltd., and Fujisawa Pharmaceutical Co., Ltd., merged to form a new corporation named Astellas Pharma, Inc. The company said its focus will be on developing breakthrough products in various areas, including urology. The company will continue to support such drugs as solifenacin succinate (Vesicare) for the treatment of overactive bladder, tamsulosin hydrochloride (Flomax) for the treatment of BPH, and tacrolimus (Prograf) for the prevention of the treatment of organ rejection after liver and kidney transplants.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests potential diuretic effect with nadofaragene firadenovec
2
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
3
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











